Details of the Drug Combinations

General Information of This Drug (ID: DMJZHT1)

• Drug Name: Tadalafil (DMJZHT1)
• Synonyms: ADCIRCA; Acdirca; Cialis; Tadanafil; Lilly brand of tadalafil; Tadalafil [USAN]; GF 196960; IC 351; ICOS 351; Ic351; Cialis (TN); GF-196960; IC-351; KS-1117; Tadalafil (JAN/USAN/INN); Cialis, GF 196960, IC 351, ICOS 351, Tadalafil; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione

Indication

Benign prostatic hyperplasia; ICD 11: GA90; Status: Approved [1]; Erectile dysfunction; ICD 11: HA01.1; Status: Approved [2]; Plasma cell myeloma; ICD 11: 2A83.1; Status: Approved [1]; Pulmonary hypertension; ICD 11: BB01; Status: Approved [1]; Priapism; ICD 11: N.A.; Status: Investigative [1]

• Therapeutic Class: Antiimpotence Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Tadalafil + Idarubicin	DCDRCVD	Idarubicin	Glioblastoma? (Cell Line: T98G)	[3]

16 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Ambrisentan + Tadalafil	DCRZVRG	Ambrisentan	Hypertension, Pulmonary	[4]
Ambrisentan + Tadalafil	DCG0IRQ	Ambrisentan	Pulmonary arterial hypertension	[5]
Gemcitabine + Tadalafil	DCH2UVW	Gemcitabine	Locally Advanced Malignant Neoplasm	[6]
Sildenafil + Tadalafil	DCLWWW5	Sildenafil	Erectile Dysfunction	[7]
Tadalafil + Sitaxsentan	DC7PMTE	Sitaxsentan	Pulmonary Arterial Hypertension	[8]
Tadalafil + Finasteride	DCO099B	Finasteride	Benign Prostatic Hyperplasia	[9]
Tadalafil + Dutasteride	DC7B0IQ	Dutasteride	Benign Prostate Hyperplasia	[10]
Tamsulosin + Tadalafil	DCZFES9	Tamsulosin	Healty Male Volunteers	[11]
Tadalafil + Hydroxyurea	DCHT9CO	Hydroxyurea	Priapism Due to Sickle Cell Disease	[12]
Selexipag + Tadalafil	DCEZKCP	Selexipag	Pulmonary Arterial Hypertension	[13]
Tadalafil + Dapoxetine	DCMD4D4	Dapoxetine	Premature Ejaculation	[14]
Tadalafil + Macitentan	DCPFSDV	Macitentan	Pulmonary Arterial Hypertension	[13]
Selegiline + Tadalafil	DCQG3VC	Selegiline	Parkinson's Disease	[15]
Solifenacin + Tadalafil	DC89HDS	Solifenacin	Benign Prostatic Hyperplasia	[16]
Tadalafil + Macitentan	DCBAP4Z	Macitentan	Pulmonary Arterial Hypertension	[17]
Tadalafil + Mirabegron	DCPXLCS	Mirabegron	Pre-diabetes	[18]

References

• [1] Tadalafil FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7299).
• [3] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [4] ClinicalTrials.gov (NCT01178073) A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] ClinicalTrials.gov (NCT01903083) Chemoimmunotherapy and Radiation in Pancreatic Cancer
• [7] ClinicalTrials.gov (NCT01352507) A Study of Tadalafil and Sildenafil in Men With Erectile Dysfunction in China
• [8] ClinicalTrials.gov (NCT01244620) A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses
• [9] ClinicalTrials.gov (NCT01139762) A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
• [10] ClinicalTrials.gov (NCT01942551) Safety and Pharmacokinetic Interaction Study of Tadalafil and Dutasteride
• [11] ClinicalTrials.gov (NCT02247505) CKD-397 Drug-drug Interaction Study (B)
• [12] ClinicalTrials.gov (NCT05142254) A Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study
• [13] ClinicalTrials.gov (NCT02558231) The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
• [14] ClinicalTrials.gov (NCT04361305) Observational Study of Pharmacological Treatment for Premature Ejaculation Concurrent With Erectile Dysfunction
• [15] ClinicalTrials.gov (NCT02225548) Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
• [16] ClinicalTrials.gov (NCT05494567) Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB
• [17] ClinicalTrials.gov (NCT02968901) Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)
• [18] ClinicalTrials.gov (NCT05051436) The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics